Dual-action inhibitors of proteolytic enzymes: potential therapeutic agents for cystic fibrosis and related ailments.
Groutas
W C
WC
Department of Chemistry, Wichita State University, KS 67208.
Huang
H
H
Venkataraman
R
R
Houser-Archield
N
N
Epp
J B
JB
D000595:Amino Acid Sequence; D001241:Aspirin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000201:enzymology; D015195:Drug Design; D006801:Humans; D066298:In Vitro Techniques; D007660:Ketoprofen / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D007700:Kinetics; D007962:Leukocytes / Q000201:enzymology; D008969:Molecular Sequence Data; D015394:Molecular Structure; D009842:Oligopeptides / Q000737:chemistry; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors* / Q000097:blood; D011480:Protease Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D012439:Saccharin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship
D009842:Oligopeptides; D011480:Protease Inhibitors; D007660:Ketoprofen; D010196:Pancreatic Elastase; D012439:Saccharin; D001241:Aspirin